drugset / Trial / NCT07384377
JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan
RandomizedParallel-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the efficacy and safety of JSKN003 Versus Physician Choiced Treatment in Patients With HER2-positive and Advanced Colorectal Cancer Who had Failed to Respond to Oxaliplatin, 5-Fu, and Irinotecan subjects.
Timeline
- Start
- 2026-02-06
- Primary completion
- 2027-11-30
- Completion
- 2028-06-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Fruquintinib | Small molecule | 5 mg | — |
| Comparator | JSKN003 | Monoclonal antibody | 6.3 mg/kg | Intravenous |
| Comparator | Regorafenib | Small molecule | 160 mg | — |
| Comparator | TAS-102 | Small molecule | 35 mg/m2 | — |